Fludarabine (NSC 118218)

For research use only. Not for use in humans.

目录号：S1491 别名： FaraA, Fludarabinum 中文名称：氟达拉滨

Fludarabine (NSC 118218) Chemical Structure

CAS No. 21679-14-1

Fludarabine (NSC 118218, FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂，特异性降低STAT1蛋白质水平（和mRNA水平），而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1032.75	现货
10mg	RMB 810.59	现货
50mg	RMB 2525.07	现货
100mg	RMB 3836.33	现货
200mg	RMB 7289.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献114篇：

Cell Metab, 2021, 33(1):110-127.e5

PubMed: 33171124 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(3):564-579

PubMed: 32130883 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(10):943-954

PubMed: 30150681 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):757-774

PubMed: 30423296 ( click the link to review the publication )

Cell Rep, 2021, 34(1):108584

PubMed: 33406422 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):322

PubMed: 34462423 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(8):12160-12178

PubMed: 33901014 ( click the link to review the publication )

Lab Invest, 2021, 10.1038/s41374-021-00618-1

PubMed: 34108631 ( click the link to review the publication )

Ann Transl Med, 2021, 9(5):365

PubMed: 33842586 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00637-8

PubMed: 34048810 ( click the link to review the publication )

Int J Med Sci, 2021, 18(15):3437-3451

PubMed: 34522170 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Clinics (Sao Paulo), 2021, 76:e2348

PubMed: 33681944 ( click the link to review the publication )

Liver Int, 2021, 10.1111/liv.14816

PubMed: 33555112 ( click the link to review the publication )

Blood Adv, 2021, 5(14):2863-2878

PubMed: 34297045 ( click the link to review the publication )

Blood Adv, 2021, 5(17):3497-3510

PubMed: 34432864 ( click the link to review the publication )

Cell Res, 2020, 1-10

PubMed: 33159154 ( click the link to review the publication )

Sci Adv, 2020, 29;6(18):eaax7881

PubMed: 32494661 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107825

PubMed: 32610126 ( click the link to review the publication )

Haematologica, 2020, 16 pii: haematol

PubMed: 32299906 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):34

PubMed: 32296043 ( click the link to review the publication )
Signal Transduct Target Ther, 2020, 10;5:34

PubMed: 32284883 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(1):122-133

PubMed: 31836351 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):30

PubMed: 32093731 ( click the link to review the publication )

Exp Neurol, 2020, S0014-4886(20)30337-X

PubMed: 33065077 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Life Sci, 2020, 265:118832

PubMed: 33259866 ( click the link to review the publication )

Cardiovasc Diagn Ther, 2020, 10(4):738-751

PubMed: 32968630 ( click the link to review the publication )

Scand J Immunol, 2020, e12981

PubMed: 33031600 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 4

PubMed: 32248559 ( click the link to review the publication )

Exp Lung Res, 2020, 1-9

PubMed: 33238771 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0228302

PubMed: 32628668 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Front Immunol, 2020, 11:1303

PubMed: 32655571 ( click the link to review the publication )

Microb Pathog, 2020, 142:104112

PubMed: 32126255 ( click the link to review the publication )

Int J Biol Macromol, 2020, 147:616-628

PubMed: 31931060 ( click the link to review the publication )

Cell Mol Immunol, 2020, 10.1038/s41423-019-0345-7

PubMed: 31900460 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(3):292-308

PubMed: 32024640 ( click the link to review the publication )

J Microbiol Immunol Infect, 2020, 25 pii: S1684-1182(20)30001-3

PubMed: 32033858 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):112

PubMed: 32169104 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )
Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Mucosal Immunol, 2019, 10.1038/s41385-019-0178-9

PubMed: 31182817 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

PLoS Pathog, 2019, 15(11):e1008037

PubMed: 31725811 ( click the link to review the publication )

Mol Ther Oncolytics, 2019,

PubMed: 30775418 ( click the link to review the publication )

Front Immunol, 2019, 10:1622

PubMed: 31379827 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2618-2633

PubMed: 31911850 ( click the link to review the publication )

J Immunol, 2019, 202(11):3173-3186

PubMed: 30996000 ( click the link to review the publication )

Int J Biol Macromol, 2019, 136:980-993

PubMed: 31220493 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Gut Pathog, 2019, 11:23

PubMed: 31123503 ( click the link to review the publication )

Immunobiology, 2019, 224(3):388-396

PubMed: 30846331 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

J Microbiol Immunol Infect, 2019, S1684-1182(18)30306-2

PubMed: 31296484 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(12):1944-1957

PubMed: 31554639 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30317

PubMed: ( click the link to review the publication )

J Cell Biol, 2018, 217(4):1503-1519

PubMed: 29507126 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Oncogene, 2018, 37(17):2270-2284

PubMed: 29391602 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):459

PubMed: 29686406 ( click the link to review the publication )

Br J Cancer, 2018, 118(4):509-521

PubMed: 29348488 ( click the link to review the publication )
Expert Opin Ther Targets, 2018, 22(6):547-557

PubMed: 29702007 ( click the link to review the publication )

J Virol, 2018, 92(22)e00728-18

PubMed: 30185587 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5975-5986

PubMed: 29496996 ( click the link to review the publication )

J Inorg Biochem, 2018, 186:235-245

PubMed: 29990747 ( click the link to review the publication )

Hum Immunol, 2018, 79(12):869-875

PubMed: 30316971 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Neuron, 2017, 96(6):1290-1302

PubMed: 29268096 ( click the link to review the publication )

Nat Commun, 2017, 8:15207

PubMed: 28488695 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Leukemia, 2017, 31(2):340-349

PubMed: 27431016 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Brain Behav Immun, 2017, 60:161-173

PubMed: 27742579 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(5):585-597

PubMed: 28108623 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Sci Rep, 2017, 7(1):14416

PubMed: 29089548 ( click the link to review the publication )

Clin Immunol, 2017, 175:56-68

PubMed: 27940139 ( click the link to review the publication )

J Cell Biochem, 2017, 118(10):3249-3259

PubMed: 28262979 ( click the link to review the publication )

Inflammation, 2017, 40(5):1726-1734

PubMed: 28656529 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

Mol Med Rep, 2017, 16(5):6405-6411

PubMed: 28901399 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0180244

PubMed: 28665978 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

J Exp Med, 2016, 19;213(10):2209-26

PubMed: 27621415 ( click the link to review the publication )

Cancer Res, 2016, 76(4):818-30

PubMed: 26837767 ( click the link to review the publication )
Am J Physiol Renal Physiol, 2016, 310(11):F1284-94

PubMed: 26984954 ( click the link to review the publication )

Int Immunopharmacol, 2016, 36:199-204

PubMed: 27160867 ( click the link to review the publication )

FEBS Lett, 2016, 590(1):53-67

PubMed: 26762170 ( click the link to review the publication )

Biogerontology, 2016, 17(5-6):907-920

PubMed: 27484416 ( click the link to review the publication )

Oncotarget, 2016, 8(31):50570-50581

PubMed: 28881584 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Eur J Immunol, 2015, 45(10):2834-46

PubMed: 26255980 ( click the link to review the publication )

Phytother Res, 2015, 29(7):1088-96

PubMed: 25881570 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):61-9

PubMed: 26044347 ( click the link to review the publication )

Mol Med Rep, 2015, 12(6):7869-76

PubMed: 26497667 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

J Allergy Clin Immunol, 2015, 136(6):1690-1694

PubMed: 26371842 ( click the link to review the publication )

Basic Res Cardiol, 2014, 109(4):419

PubMed: 24907869 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1512

PubMed: 25375377 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2276-87

PubMed: 25122069 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9952-60

PubMed: 24550394 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

靶点

STAT1 ^[4]
(Vascular smooth muscle cells)

体外研究

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量，并伴随着处于细胞周期S期细胞数量的减少，对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase，-8，- 9和- 3，- 7的剪切，继而诱导PARP的剪切。氟达拉滨以时间梯度增加Bax基因表达，而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时，处理后细胞膜电位降低，61.05%的细胞表达低荧光罗丹明123，而未处理的对照组细胞仅为8.62%^[1]。为提高溶解度，Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine)，在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸（(F-ara-ATP）。该代谢产物抑制了DNA复制的几个关键过程，如DNA合成所需酶，比如核糖核酸还原酶，DNA引发酶，DNA聚合酶，具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶^[2]。通过检测ICAM - 1的表达和IL - 8释放，表明Fludarabine还可以诱导前炎症刺激单核细胞的增加^[3]。Fludarabine对卵巢癌细胞系生长无影响，而它对黑色素瘤细胞系有明显的剂量依赖性抑制^[4]。Fludarabine诱导显著降低STAT - 1磷酸化，但不改变JAK 2活性。磷酸Fludarabine对三种STAT蛋白磷酸化影响不显着。Fludarabine（1.5mg）在处理2天后和7天后显著降低磷酸化STAT - 1和STAT-1总蛋白量^[5]。磷酸化JAK 2在处理后第2天变化不明显，处理后第7天的JAK表达明显受抑制。Fludarabine不影响其他STAT蛋白质，特异性抑制STAT - 1激活以降低血管平滑肌细胞体外增殖。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Jeko-1	M4Gz[GZ2dmO2aX;uJGF{e2G7	MUKyNEDPxE1?	NIfIN5UzPCCq		NF7SPXdqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=>	M3;kcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUSwO\|EzLz5{NUm0NFcyOjxxYU6=
MV-4-11	M3jwOWFxd3C2b4Ppd{BCe3OjeR?=	MXuyMlUh\|ryP	NVTjdJN1PDhiaB?=		NVXUTolmcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	NUDMXnZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
THP-1	Mke0RZBweHSxc3nzJGF{e2G7	MkW0Nk42KM7:TR?=	NVzjRYdoPDhiaB?=		MXHpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	M2PoUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
MOLM 13	MkHlRZBweHSxc3nzJGF{e2G7	NF3oR4UzNjVizszN	NHnqWJY1QCCq		NWLpfI06cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	M1Hz[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
KBM3/Bu2506	NXq5OJpFSXCxcITvd4l{KEG\|c3H5	MVmyMlUh\|ryP	MX20PEBp		MWrpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzMUW4N{c,OjVzMUG1PFM9N2F-
Nalm-6	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTF6IN88US=>	Mn;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Reh	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoW5TWM2OD1\|MDFOwG0>	NVvFNIEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
U2937	NXPWR\|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HPN2lEPTB;MU[g{txO	MmjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Mec-1	M4fwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1K0cmlEPTExvK61NFAh\|ryP	M1n6V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
RPMI-8226	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHOTWM2OD13MECg{txO	NVXCfpBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
Molt-4	NYnGO3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYexd\|dNUUN3ME2xPFAh\|ryP	NVj2WVQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
Nalm-6-FluR	NEP5TXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF65W5NKSzVyPUK1NEDPxE1?	M4HtVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
Raji	Mn\6SpVv[3Srb36gRZN{[Xl?	MVmzxsDPxE1?	NHfIdXozPC92OD:3NkBp		Mn\kbY5lfWOnczDhZ4N2dXWuYYTpc45{KG:oIIC1N{wheDZ\|IHHu[EBxPzQEoB?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2ME[5OUc,OjR7NEC2PVU9N2F-
PBMC	MmTpSpVv[3Srb36gRZN{[Xl?	Ml\3OVAwOTByIN88US=>	NXrJTY1QOjRiaB?=	NUDKOIliTE2VTx?=	MmTobY5pcWKrdIOgV3RCXDFicHjvd5Bpd3K7bHH0bY9v	MnmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
MDA-231	NHrx[FRHfW6ldHnvckBCe3OjeR?=	M1TBSVExOCEQvF2=	NHrvbnQzPCCq	NYrIUphxTE2VTx?=	MmfK[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w	NHnydYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
624.38mel	NX23NG44TnWwY4Tpc44hSXO\|YYm=	MnjjOVAh\|ryP	MnH3NlQhcA>?	MYrEUXNQ	NH6zZpZl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36=	NYjnUHRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
MDA-231	MknxSpVv[3Srb36gRZN{[Xl?	MoPLOVAuOjByIN88US=>	MYKyOEBp	NHexcXZFVVOR	Ml[2bY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN?	NFrOb\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
624.38mel	MkXQSpVv[3Srb36gRZN{[Xl?	NXTxTolDPTBvMkCwJO69VQ>?	M3nRflI1KGh?	NF3HRXZFVVOR	M2LsWolvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy\|	M4WwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUGxPFczLz5{NEmxNVg4OjxxYU6=
HMECs	NWXnN5lWTnWwY4Tpc44hSXO\|YYm=	NFO1XlQyODEEoN88UeKh	Mn7PN\|bDqGh?		NXHQfHpzcW6qaXLpeJMhUU[QzsRCpIFv\CCOUGOgbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnSSlEh\XiycnXzd4lwdg>?	MmPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUGzNlcoRjJ2MkGxN\|I4RC:jPh?=
HMECs	NU\tcIdrTnWwY4Tpc44hSXO\|YYm=	NYfUT\|BnOTBywrFOwG3DqA>?	NFrZNWU{PsLiaB?=		MonpbY5pcWKrdIOgTWZP\|rIEoH3l[IlifGWmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSCjbnSgV3RCXDNuIHL1eEBvd3Rib3[gV3RCXDJ?	NVL2R3U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVE{OjdpPkK0NlEyOzJ5PD;hQi=>
BJAB	MWPBdI9xfG:\|aYOgRZN{[Xl?	M33WZVXDqM7:TR?=	M3nmZlI1KGh?		NGP0[IZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M1P0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEW3NVQ4Lz5{NEC1O\|E1PzxxYU6=
I-83	M3\MW2Fxd3C2b4Ppd{BCe3OjeR?=	NFnwcFI2yqEQvF2=	NVzvWGRGOjRiaB?=		MYPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
NALM6	NUDjSJpwSXCxcITvd4l{KEG\|c3H5	NIH6VoQ2yqEQvF2=	MUiyOEBp		M4G1TIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
DU-145	M{HRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPod4tUOC1zMDFOwIcwdWx?	MkDZOFghcMLi		NFvKdYJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd\|NEixOUc,OjN5M{S4NVU9N2F-
Nalm-6	NFLSW5ZHfW6ldHnvckBCe3OjeR?=	MUWxNOKh\|ryP	Mkj0NU8zNzRiaB?=		NYfLSJlMcW6mdXPld{BifXSxcHjh[5k>	NWPDXHljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFEzOjNpPkKzOlgyOjJ\|PD;hQi=>
Reh	NGiyb5lHfW6ldHnvckBCe3OjeR?=	MoX3NVDDqM7:TR?=	NXzLO2ZqOS9{L{SgbC=>		M{nqbIlv\HWlZYOgZZV1d3CqYXf5	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
Nalm-6	NX;PNVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoGyTWM2OCEkiMyxNQKBkc7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
Reh	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm4RYdYUUN3MDFijNwyOOLCid88US=>	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEGyNlMoRjJ\|NkixNlI{RC:jPh?=
HEC1A	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HrbFExOC13MECg{txO	MnnSNlQhcA>?		NHLwU41qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NUfjWmM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17ucVExOC13MECg{txO	M{DqNVI1KGh?		M2PTSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC50B	M2rhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rrZlExOC13MECg{txO	NGCzPIMzPCCq		NHTJOXpqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	NXXBO2c6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
HEC1A	MXLBdI9xfG:\|aYOgRZN{[Xl?	NWSzWGhKOjBxMUCwJO69VQ>?	MXSyOEBp		NFLIVnlqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M2HiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
AN3CA	Mk[2RZBweHSxc3nzJGF{e2G7	MW[yNE8yODBizszN	NF\5W5kzPCCq		M4jZfYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC50B	M1HGeGFxd3C2b4Ppd{BCe3OjeR?=	MYqyNE8yODBizszN	NETRS4MzPCCq		NXXIfpc1cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
EHEB	M2rwT2Fxd3C2b4Ppd{BCe3OjeR?=	MVS0NEDPxE1?	NInKW4QzPCCq		NXvydJR2cW6mdXPld{BieG:ydH;zbZM>	MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUewO\|UoRjJ\|NEm3NFc2RC:jPh?=
A549	M{TsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnGzTWM2OD1zNT63xtEzNjhiwsXN	M1u3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e3NVkzLz5{M{O3O\|E6OjxxYU6=
A549 GAPDH-deficient	M{\ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDFTWM2OD1zOD61xtEzNjNiwsXN	Mn;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|N{exPVIoRjJ\|M{e3NVkzRC:jPh?=
CLL	M4fwO2Fxd3C2b4Ppd{BCe3OjeR?=	NWfONXV4OTBizszNxsA>	M2XhZVI1NTl4IHi=		M2nEfYlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg>	MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MEe2PFYoRjJ{MkC3Olg3RC:jPh?=
MEC1	Ml7SRZBweHSxc3nzJGF{e2G7	M4LjNFExOMLizszN	NWH4XpgzPzJiaB?=		MXjpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NWPIUVZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxN\|I6PzNpPkKyNVMzQTd\|PD;hQi=>
U937	Mk\iRZBweHSxc3nzJGF{e2G7	NULSZoRwOC56IN88US=>	NV7zW41OPC12ODDo		Mk\BbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	NYrLfJUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|Q4ODBpPkKyNFc1PzByPD;hQi=>
U937	MVzBdI9xfG:\|aYOgRZN{[Xl?	NHTXfY0yKM7:TR?=	MoPPPVYhcA>?		NUm1UXc3cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	NFjBc5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN\|UzOyd-MkKwNlM2OjN:L3G+
Daudi	Mnj3RZBweHSxc3nzJGF{e2G7	NX75XFNoOjBizszN	MVG5OkBp		MoPXbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	M2nmfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEKzOVI{Lz5{MkCyN\|UzOzxxYU6=
J45.01	NWLVV\|FkSXCxcITvd4l{KEG\|c3H5	MWKxJO69VQ>?	MlXGPVYhcA>?		NHvEe2FqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	M1T2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEKzOVI{Lz5{MkCyN\|UzOzxxYU6=
RPMI 8226	M4jXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{f6TmlEPTB;MkWuPeKhyrIEoEOuO{DPxE1?	NFvxeJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
CEM	NIPKZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7DbpJKSzVyPUKuOOKhyrIEoECuOEDPxE1?	NHfJZ5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
Raji	NXHGWml[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfJZldKSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?=	M{XleVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS4NlY1Lz5{MUm0PFI3PDxxYU6=
U937	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrXOIRsUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2=	M{PpUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS4NlY1Lz5{MUm0PFI3PDxxYU6=
K562	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLETWM2OD1yLkS0xsDDucLiMD6wOUDPxE1?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
NALM-6	MoTKRZBweHSxc3nzJGF{e2G7	NV7vS\|Z3OTBizszNxsA>	MoLZNlQhcA>?		NXy1XZF7cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ7OUO4N{c,OjF4OUmzPFM9N2F-
JMV-3	NEPa[5FCeG:ydH;zbZMhSXO\|YYm=	NUHNUoVEOTBizszNxsA>	Ml73NlQhcA>?		MlP1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|bHnnbJRtgQ>?	NGrrUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[5PVM5Oyd-MkG2PVk{QDN:L3G+
EHEB	NHTS[3BHfW6ldHnvckBCe3OjeR?=	NWTnZ5A2PS13MDFOwG0>	NELQe3kzPCCq		M3j1dYRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6	NVThTZh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOlg{QTFpPkKxNVY5OzlzPD;hQi=>
JVM-2	NUf4fG1ITnWwY4Tpc44hSXO\|YYm=	NVOw[IdsOzBizszN	M2\HSVI1KGh?		NEDVfnFl\WO{ZXHz[ZMheDJzIHX4dJJme3Orb36=	MmTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNkizPVEoRjJzMU[4N\|kyRC:jPh?=
KBM3/Bu2506	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjaTm9nUUN{ME2wMlY4KML3TR?=	NWCzfGNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5N\|M2ODlpPkKwPVM{PTB7PD;hQi=>
KBM3/Bu2506	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmH4NE43KM7:TR?=	NHrPXHkzPCCq		Mm\KbY5kemWjc3XzJJRp\SClZXzsJIZz[WO2aX;uJIlvKFNvcHjhd4U>	MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{O1NFkoRjJyOUOzOVA6RC:jPh?=
MDA-MB-231	NF7rfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWW3PVRvUUN3ME20MlAh\|ryP	M2fYVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNES3N\|kxLz5{MES0O\|M6ODxxYU6=
MCF-7	M{DQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfSTWM2OD1zNT6wJO69VQ>?	NIfDVXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0O\|M6OCd-MkC0OFc{QTB:L3G+
HLE-B3	MWfGeY5kfGmxbjDBd5NigQ>?	NV;iPFhlOjVizszN	MUe0PEBp		M{DlWIJtd2OtczDJSm4u\|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44>	M{HneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO1NVU5Lz5{MESzOVE2QDxxYU6=
K562	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX31XZBTPzJiaB?=		M4nkbGlEPTB;Mz6zJI5O	M1[xT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C3NVk5Lz5{MEOwO\|E6QDxxYU6=
BW-225	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PKVmlEOjB;MT6zO{DEnzFy4pkSPOKh\|ryPwrC=	M1nvXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
OH-65	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|IxRTFwM{egx7cyOOLKkklCpO69VcLi	NX\y[3htRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
GR-145	NFvLd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D5bWlEOjB;Mj63OEDEnyBzMPMIllghKM7:TdMg	MmTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
A549	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPjSHZYUUN{ME21MlQ5KMPZIEGw5qiTQCEQvF5CpC=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ4MUO4NEc,OTh4NkGzPFA9N2F-
CaSki	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfxWFBKSzJyPUGuN\|chy5diMUFijLI4KM7:TdMg	Mm\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
ZMK-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXYVm1KSzJyPUGuN\|chy5diMUFijLI3KM7:TdMg	NH20U2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
SKW6.4	MYLBdI9xfG:\|aYOgRZN{[Xl?	M4n2NlAvODFvMUCg{txO	MYmyOE81QCCq		MlnWbY5lfWOnczDj[YxtKGSnYYToJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ?	Ml7jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyOUKzOFAoRjF6MEmyN\|QxRC:jPh?=
RPMI 8226	NISxU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1fXW\|I1KGh?		MU\JR\|UxRTFwNUVCpO69VQ>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl5NkG4Okc,OTd7N{[xPFY9N2F-
MM.1S	NEPqTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYf5OlJmPDhiaB?=		MYrJR\|UxRTF\|LkS4xsDPxE1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl5NkG4Okc,OTd7N{[xPFY9N2F-
MM.1R	Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEjmXlI1QCCq		NHfOZWxKSzVyPUOzMlc6KM7:TR?=	M3rlRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUe2NVg3Lz5zN{m3OlE5PjxxYU6=
U937	NVvBbJpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPCTG5OUUN3ME2zMFIxOCEEsTC1OlAhdk1?	MlK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7M{CzOlEoRjF3OUOwN\|YyRC:jPh?=
CLL5	M37U[2FvfGm2dX3vdkBie3OjeR?=		NVnkdYkzPDhiaILz		M4i3SWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDViY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDBwMU[g{txONg>?	MonlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
K562	MnfzR5l1d3SxeHnjbZR6KGG\|c3H5		M1OyVVczKGi{cx?=		NEDJTohEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBx[WOuaYThfIVtNXKnc3nzeIFvfCCNNU[yJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK2JO69VS5?	NWTEOIU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
CLL3	NFnTR3NCdnSrdIXtc5Ih[XO\|YYm=		NULmUZJ2PDhiaILz		MYHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDDUGw{KGOnbHzzJIl{d2yjdHXkJIZzd21iQ1zMJJBifGmnboSgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3Mh[W6jbInzbZMtKEWFNUCgQUAxNjN3IN88UU4>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
CLL4	MnG1RY51cXS3bX;yJIF{e2G7		M1PWZlQ5KGi{cx?=		NHrhSIxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx2IHPlcIx{KGm\|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSByLk[0JO69VS5?	M3\vS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
CEM-DNR-B	MofVR5l1d3SxeHnjbZR6KGG\|c3H5		M{[zWFczKGi{cx?=		NILlcYpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1vRF7SMWIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuNFEh\|ryPLh?=	NYDNeHJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
primary CLL	NEO2UmdEgXSxdH;4bYNqfHliYYPzZZk>				NUXsSXhnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKrbXHyfUBEVExiY3XscJMtKEyGNUCgQUAyNjFizszNMi=>	Mom5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNEizPVIoRjJ3MUS4N\|kzRC:jPh?=
CLL6	M1TobGFvfGm2dX3vdkBie3OjeR?=		M3K0NVQ5KGi{cx?=		M4\xOGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDZiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDFwNjFOwG0v	MlLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CLL2	NX3TTFJISW62aYT1cY9zKGG\|c3H5		NGTwO4o1QCCqcoO=		M2XXdWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDJiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDJwNk[g{txONg>?	M2PjflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
HCT116	NFvtdHNEgXSxdH;4bYNqfHliYYPzZZk>		M{DzeFczKGi{cx?=		M4K3fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPi54IN88UU4>	M4XKeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
PBMC	MoPpR5l1d3SxeHnjbZR6KGG\|c3H5		NIfvZmI1QCCqcoO=		M3O5[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHCjdHnlcpQhWEKPQzDh[pRmeiB2ODDodpMh[nliQ3XscHRqfHKnLVLseYUh[XO\|YYmgbY4heHKnc3XuZ{Bw\iCvb4Xz[UBOOjFyQkSgZ4VtdHNuIFnDOVAhRSBzMDFOwG0v	M{ewVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[yOFE4Lz5{NUW2NlQyPzxxYU6=
CHO	NHnmWlRHfW6ldHnvckBie3OjeR?=				MkfmRolv\GmwZzDh[oZqdmm2eTDk[ZRmem2rbnXkJIJ6KGSrc4DsZYNmdWWwdDDv[kB{eGWlaX\pZ{BjcW6maX7nJI9nKFtzMkXJYW4uMDRvYX3pco8uOy2rb3TvdIhmdmW2aInsLU1i\GWwb4PpcoUhcW5ibXXtZpJidmW\|IH;mJGNJVyClZXzsd{B{fGGkbImgeJJidnOoZXP0[YQhf2m2aDD0bIUhemG2IHHk[Y5we2mwZTDBN{Bz\WOncITvdkwhU2liPTCxNE41KM7:TT6=	NG\sfmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi95N{C3N\|IxLz55N{C3N\|IxRC:jPh?=
JVM2	NGTmSIhCdnSrdIXtc5Ih[XO\|YYm=				MnKzRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSm\NNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliRlHDV{BidmGueYPpd{whTUN3MDC9JFExNjRizszNMi=>	M1;xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
HeLa	MnP2RY51cXS3bX;yJIF{e2G7				NULuV5lmSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFXDOVAhRSBzNjFOwG0v	Ml:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CLL1	MUnBcpRqfHWvb4KgZZN{[Xl?		NU\DNpAzPDhiaILz		Ml7BRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOSClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTdwMTFOwG0v	NHzyVok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3N\|c{QSd-MkS2O\|M4Ozl:L3G+
CEM	NYG5emo3S3m2b4TvfIlkcXS7IHHzd4F6		NVztNoExPzJiaILz		M1znRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVkvPDlizszNMi=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNU[1Okc,OjB4MEW2OVY9N2F-
T47D	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		NUnEW\|V{PzJiaILz		MnLhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gOFYvOiEQvF2u	M2DuSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
A549	NH;TSFZEgXSxdH;4bYNqfHliYYPzZZk>		MlnDO\|IhcHK\|		Ml7CR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOFcvPDRizszNMi=>	M4XWNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
CCRF-CEM	NEXhN5dHfW6ldHnvckBie3OjeR?=	MUexNEB2VQ>?	MVmxJJRwKDZyIH3pcpM>		Mn\BSJJ2\yC2cnHud5BwenRiaX6gbJVu[W5iQ1PSSk1ETU1iY3XscJMh[XO\|ZYPz[YQh[XNiRV7UNU1u\WSrYYTl[EB2eHSja3WgZZQhOTBidV2gZYZ1\XJiMTD0c{A3OCCvaX7zJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pIHHuZYx6e2m\|	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6OEewOUc,OjN\|OEi3NFU9N2F-
TC32	NU\2PY11eUiWUzDhd5NigQ>?				Mn3MdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	Mk\vdWhVWyCjc4PhfS=>				NXz3[IFreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	MnHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MoPkdWhVWyCjc4PhfS=>				MkP1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	M2fXWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MoHldWhVWyCjc4PhfS=>				Mn;ldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M{HjO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MXzxTHRUKGG\|c3H5				NGS0eFdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	Mn\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MYjxTHRUKGG\|c3H5				NYTjRohueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	Ml\JdWhVWyCjc4PhfS=>				MmD5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NH\YPFByUFSVIHHzd4F6				NFXlTY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	M1rHe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MoDrdWhVWyCjc4PhfS=>				NX\ISpFteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MonGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NXK4XIl6eUiWUzDhd5NigQ>?				MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	M2LJN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M2ruU5FJXFNiYYPzZZk>				MlfFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NH\DPVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	Mmr6dWhVWyCjc4PhfS=>				MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	NEXnOWtyUFSVIHHzd4F6				NVXmd5h5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M4G0NZFJXFNiYYPzZZk>				NGfIfVJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	NYHqWpNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NX3lNJdWeUiWUzDhd5NigQ>?				M4ToWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN?	NV[5ToJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NVLy[VFreUiWUzDhd5NigQ>?				NGDvPVFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	NUH5PZhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NGjZToZyUFSVIHHzd4F6				MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NU\kWml2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NIjWZ2tyUFSVIHHzd4F6				NWnmfXlHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	NUHNfIdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NVnxWXZ5eUiWUzDhd5NigQ>?				NV3kTJVneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	Mn7vdWhVWyCjc4PhfS=>				M{izfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	M3T6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NHrkfWFyUFSVIHHzd4F6				NWHETGh3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	NWrESoFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MUPxTHRUKGG\|c3H5				MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	NFrSOVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	MVTxTHRUKGG\|c3H5				M{faRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NX;MR\|RqeUiWUzDhd5NigQ>?				NXjsXGd1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M{PWOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	Mo\SdWhVWyCjc4PhfS=>				NHPrXIxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Daoy	M3vL[JFJXFNiYYPzZZk>				MnzRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBF[W:7IHPlcIx{	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	M4DFbJFJXFNiYYPzZZk>				MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	M3izO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NIHvcmVyUFSVIHHzd4F6				NGH5fmNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	NXvkU4hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	M1HMTZFJXFNiYYPzZZk>				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	NWH1ZmJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MmnXdWhVWyCjc4PhfS=>				M120eJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	Mni5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NGfURWJyUFSVIHHzd4F6				MknKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NFHnRVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NX;pS\|lseUiWUzDhd5NigQ>?				MknsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M4TDTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NI\vfmJyUFSVIHHzd4F6				M3jWV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NXG5R\|Y2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MYTxTHRUKGG\|c3H5				M3TqcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MonOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NHzxO4hyUFSVIHHzd4F6				MoHXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	NGf1Z449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NH;EelFyUFSVIHHzd4F6				MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	M3OxRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MkfvdWhVWyCjc4PhfS=>				NE\JeldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy\|	MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	M1PjNJFJXFNiYYPzZZk>				NG\tXVVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	M3e2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NH\VOnhyUFSVIHHzd4F6				M1r3e5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	NVTHbVQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NGXPfVJyUFSVIHHzd4F6				NHPWZlNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	MmPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MUPxTHRUKGG\|c3H5				M4L6OpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NW\J[ohGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MU\xTHRUKGG\|c3H5				M{\NVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhWkRiY3XscJM>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	procaspase-9 / procaspase-3; PubMed: 27223263 Oncotarget Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control. p-p53 / p53; PubMed: 27223263 Oncotarget (A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒ STAT1; PubMed: 26677135 Int J Mol Med Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.	27223263 26677135
Immunofluorescence	α-SMA / Vimentin; PubMed: 28322315 Sci Rep FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).	28322315
Growth inhibition assay	Cell viability ; PubMed: 24956101 PLoS One CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.	24956101

体内研究

PBS对照组中肿瘤细胞增长迅速，25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。^[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

细胞实验： ^[1]	- 合并 Cell lines: 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系 Concentrations: 2 μg/Ml Incubation Time: 24 小时 Method: 对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 10⁵细胞密度铺板，实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定，离心后用含100μg/mL核糖核酸酶PBS重悬浮，37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中，用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL（末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记）法和原位细胞凋亡检测试剂盒处理细胞，最后用流式细胞仪分析。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠 Dosages: 40 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	57 mg/mL (199.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Fludarabine (NSC 118218) SDF

分子量	285.23
化学式	C₁₀H₁₂FN₅O₄
CAS号	21679-14-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	FaraA, Fludarabinum

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526795	Recruiting	Drug: Cytarabine\|Drug: Fludarabine\|Drug: Pegcrisantaspase	Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent T-Cell Prolymphocytic Leukemia\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	April 9 2021	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to re-suspend and deliver the inhibitor for in vivo experiments?
回答：
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

研究领域

产品类型

定制您的化合物库

Fludarabine (NSC 118218)

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献114篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Fludarabine (NSC 118218) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品